ArriVent Announced Sunday, Initial Phase 1 Data For CDH17-Targeted ADC ARR-217 In Gastrointestinal Cancers At ESMO, Demonstrating 44.8% Objective Response Rate At 6mg/kg Dose In Late-Line Colorectal Cancer Patients
ARR-217 was generally well-tolerated. ArriVent to host virtual webinar on Monday, October 26, 2026, at 8 am ET to discuss the data from the ARR-217 program
Share
Why It Matters
ArriVent showed early test results for a cancer medicine. About 45% of patients had their tumors shrink, which is a positive sign to watch.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.